Drug-Resistant Schizophrenia: Treatment Options

CNS Drugs

Volumn 5, Issue 1, 1996, Pages 8-23

  Jalenques, Isabelle ^a  

^a Hopital Saint Jacques Clermont Ferrand   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LEVODOPA; LEVOMEPROMAZINE; LITHIUM; LOXAPINE; RESERPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE;

CLINICAL TRIAL; ELECTROCONVULSIVE THERAPY; HUMAN; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SCHIZOPHRENIA;

EID: 0030064082     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199605010-00002     Document Type: Article

References (182)

1. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988 Sept; 45: 789-95
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington, DC: American Psychiatric Association, 1987
3. May PR, Dencker SJ, Hubbard JW, et al. A systematic approach to treatment resistance in schizophrenic disorders. In: Dencker SJ, Kulhanek F, editors. Treatment resistance in schizophrenia. Braunschweig/Wiesbaden: Vieweg, 1988: 22-33
4. Brenner H, Dencker SJ, Goldstein M, et al. Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990; 16: 551-61
5. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962; 10: 799-812
6. Kay SR, Opler LA, Fiszbein A. Significance of positive and negative syndromes in chronic schizophrenia. Br J Psychiatry 1986; 149: 439-48
7. Andreasen NC, Olsen S. Negative vs positive schizophrenia. Definition and validation. Arch Gen Psychiatry 1982; 39: 789-94
8. Andreasen NC. Positive vs negative schizophrenia, a critical evaluation. Schizophr Bull 1985; 11: 380-9
9. Wallace CJ. Functional assessment in rehabilitation. Schizophr Bull 1986; 12: 604-30
10. Davis JM, Schaffer CB, Killian GA, et al. Important issues in the drug treatment of schizophrenia. Schizophr Bull 1980; 6: 70-87
11. Marder SR, Ames D, Wirshing WC, et al. Schizophrenia. Psychiatr Clin North Am 1993; 16, 3: 567-87
12. Tuma AH, May PRA. And if that doesn't work, what next?... A study of treatment failures in schizophrenia. J Nerv Ment Dis 1979; 167: 566-71
13. Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994; 151 (10): 1409-16
14. Kolakowska T, Williams AO, Ardern M, et al. Schizophrenia with good and poor outcome. I: Early clinical features, response to neuroleptics and signs of organic dysfunction. Br J Psychiatry 1985; 146: 229-46
15. Kolakowska T, Williams AO, Jambor K, et al. Schizophrenia with good and poor outcome. III: Neurological soft signs, cognitive impairment and their clinical significance. Br J Psychiatry 1985; 146: 348-57
16. Collins EJ, Hogan TP, Awad MD. The pharmacoepidemiology of treatment-refractory schizophrenia. Can J Psychiatry 1992; 37: 192-5
17. Keefe RSE, Mohs RC, Davidson M, et al. Kraepelinian schizophrenia: a subgroup of schizophrenia? Psychopharmacol Bull 1988; 24: 56-61
18. Kinon BJ, Kane JM, Chakos M, et al. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects. Psychopharmacol Bull 1993; 29 (3): 365-9
19. Kinon BJ, Kane JM, Johns C, et al. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull 1993; 29 (2): 309-14
20. Bareggi SR, Mauri M, Cavallaro R, et al. Factors affecting the clinical response to haloperidol therapy in schizophrenia. Clin Neuropharmacol 1990; 13 Suppl. 1: 29-34
21. Prudo R, Munroe Blum H. Five-year outcome and prognosis in schizophrenia: a report from the London Field Research Centre of the international pilot study of schizophrenia. Br J Psychiatry 1987; 150: 345-54
22. Breier A, Schreiber JL, Dyer J, et al. National Institute of Mental Health longitudinal study of chronic schizophrenia. Arch Gen Psychiatry 1991; 48: 239-46
23. Pickar D, Owen RR, Litman RE, et al. Clinical and biological response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49: 345-53
24. Duncan E, Wolkin A, Angrist B, et al. Plasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenics. Biol Psychiatry 1993; 34: 523-8
25. Itil TM, Shapiro D, Schneider SJ, et al. Computerized EEG as a predictor of drug response in treatment resistant schizophrenics. J Nerv Ment Dis 1980; 169: 629-37
26. Crow TJ. Current view of the type II syndrome: significance of age of onset, intellectual impairment, and structural changes in the brain. In: Greden JF, Tandon R, editors. Negative schizophrenic symptoms: pathophysiology and clinical implications. Washington, DC: American Psychiatric Press, 1991: 161-71
27. Friedman L, Knutson L, Shurell M, et al. Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia. Biol Psychiatry 1991; 29: 865-77
28. Lieberman JA, Jody D, Alvir JMJ, et al. Brain morphologic features, dopamine, eye-tracking abnormalities in first episode schizophrenia: prevalence and clinical correlates. Arch Gen Psychiatry 1993; 50: 357-68
29. Pearlson GD, Marsh L. Magnetic resonance imaging in psychiatry. In: Oldham JM, Riba MB, Tasman A, editors. American Psychiatric Press review of psychiatry. Vol 12. Washington, DC: American Psychiatric Press, 1993: 347-81
30. Farde L, Wiese FA, Haldin C, et al. Central D2 dopamine receptors occupancy in schizophrenia patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988; 45: 71-6
31. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17: 325-51
32. Boodhoo JA. Anticholinergics and antiparkinsonian drugs in psychiatry. Br J Hosp Med 1991; 46: 167-9
33. Soni SD, Bamrah JS, Krska J. Effects of alcohol on serum fluphenazine levels in stable, chronic schizophrenics. Hum Psychopharmacol 1991; 6: 301-6
34. Miller DD, Kelly MW, Perry PJ, et al. The influence of cigarette smoking on haloperidol pharmacokinetics. Biol Psychiatry 1990; 28: 529-31
35. Van Putten T, May PRA, Marder SR. Response to antipsychotic medication: the doctor's and the consumer's view. Am J Psychiatry 1984; 141: 16-9
36. Johnson DAW. Drug treatment of schizophrenia. In: Bebbington P, McGuffin P, editors. Schizophrenia the major issues. Oxford: Heineman Professional Publishing, 1988: 158-71
37. Vaughn CE, Snyder KS, Jones S, et al. Family factors in schizophrenic relapse. Arch Gen Psychiatry 1984; 41: 1169-77
38. Hogarty GE. Resistance of schizophrenic patients to social and vocational rehabilitation. In: Dencker SJ, Kulhanek F, editors. Treatment resistance in schizophrenia. Braunschweig/Wiesbaden: Vieweg, 1988: 83-97
39. Berrios GE. Neuroleptic-refractory patients and their drug plasma levels. Encéphale 1982; 8: 465-85
40. Prien RF, Cole JO. High dose chlorpromazine therapy in chronic schizophrenia. Arch Gen Psychiatry 1968; 18: 482-95
41. Lader M, Herrington R. Biological treatments. Oxford: Oxford University Press, 1990
42. Lal S, Nair NPV. Is levomepromazine a useful drug in treatment-resistant schizophrenia? Acta Psychiatr Scand 1992; 85: 243-5
43. Rifkin A, Quitkin F, Carrillo C, et al. Very high dosage fluphenazine for nonchronic treatment-refractory patients. Arch Gen Psychiatry 1971; 25: 398-403
44. Quitkin F, Rifkin A, Klein DF. Very high dosage vs standard dosage fluphenazine in schizophrenia. A double-blind study of nonchronic treatment-refractory patients. Arch Gen Psychiatry 1975; 32: 1276-81
45. Prien RF, Kevine J, Cole JO. High dose trifluoperazine therapy in chronic schizophrenia. Am J Psychiatry 1969; 126: 305-13
46. Lehmann CR, Ereshefsky L, Saklad SR, et al. Very high dose loxapine in refractory schizophrenic patients. Am J Psychiatry 1981; 138 (9): 1212-4
47. Ereshefsky L, Saklad SR, Mings TE, et al. Management of chronic, refractory schizophrenic patients with high-dose loxapine. Psychopharmacol Bull 1983; 19 (4): 600-3
48. Baldessarini RJ, Cohen CM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988; 45: 79-91
49. Van Putten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990; 47: 754-8
50. Rifkin A, Doddi S, Karajgi B, et al. Dosage of haloperidol for schizophrenia? Arch Gen Psychiatry 1991; 48: 166-70
51. Volavka J, Cooper T, Czobor P, et al. Haloperidol blood levels and clinical effects. Arch Gen Psychiatry 1992; 49: 354-61
52. Curry SH, Marshall JHL, Davis JM, et al. Chlorpromazine plasma levels and effects. Arch Gen Psychiatry 1970; 22: 289-96
53. Van Putten T, Marshall BD, Liberman R, et al. Systematic dosage reduction in treatment-resistant schizophrenic patients. Psychopharmacol Bull 1993; 29 (2): 315-20
54. Hirsch SR, Barnes TRE. Clinical use of high-dose neuroleptics. Br J Psychiatry 1994; 164: 94-6
55. Meltzer HY. Clozapine: clinical advantages and biochemical mechanisms in schizophrenia. In: Tamminga C, editor. Schizophrenia: a scientific focus. New York: Oxford University Press, 1989
56. Shaik S, Collier D, Kerwin RW, et al. Dopamine D4 receptor subtypes and response to clozapine. Lancet 1993; 341: 116
57. Kerwin RW. The new atypical antipsychotics. Br J Psychiatry 1994; 164: 141-8
58. Clozapine and loxapine for schizophrenia. Drug Ther Bull 1991; 29 (Pt 11): 41-2
59. Nyberg S, Farde L, Eriksson L. 5HT2 and D2 dopamine receptor occupancy in the living human brain. A living human study with risperidone. Psychopharmacology (Berl) 1993; 110: 265-72
60. Kerwin RW. Atypical antipsychotics: a history of the concept and recent research. Schizophr Monitor 1993; 3 (Pt 2): 1-4
61. Lieberman JA. Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and development. Br J Psychiatry 1993; 163 (22 Suppl.): 7S-18S
62. Meltzer HY, Bastani B, Kwon KY, et al. A prospective study of clozapine in treatment-resistant patients. I. Preliminary report. Psychopharmacology (Berl) 1989; Suppl. 93: 68S-72S
63. Paunovic VR, Marinkovic D, Timolijevic I, et al. Clozapine in the treatment of negative syndrome in schizophrenia: a three-year follow-up study [abstract]. 17th Congress, Collegium International Neuro-Psychopharmacologicum; 1990 10-14 Sept; Kyoto, 291
64. Tandon R, Goldman R, DeQuardo JR, et al. Positive and negative symptoms covary during clozapine treatment in schizophrenia. J Psychiatr Res 1993; 27 (4): 341-7
65. Lindenmayer JP, Grochowski S, Mabugat L. Clozapine effects on positive and negative symptoms: a six-month trial in treatment-refractory schizophrenics. J Clin Psychopharmacol 1994; 14 (3): 201-4
66. Jalenques I, Coudert AJ. Clozapine and treatment-resistant schizophrenic patients: a long term prospective study in twenty patients (in French). Encéphale 1994; XX: 767-75
67. Miller DD, Perry PJ, Cadoret RJ, et al. Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Compr Psychiatry 1994; 35 (1): 8-15
68. Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151: 20-6
69. Jalenques I, Albuisson E. Improvement of negative-symptoms during clozapine treatment in neuroleptic-resistant schizophrenics [abstract]. Proceedings of Critical Issues in the Treatment of Schizophrenia. International Academy for Biomedical and Drug Research; 1995 March 10-12: Florence, 155
70. Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med 1991; 324 (11): 746-54
71. Alvir JM, Lieberman JA. A reevaluation of the clinical characteristics of clozapine-induced agranulocytosis in light of the United States experience. J Clin Psychopharmacol 1994; 14 (2): 87-9
72. Meltzer HY. Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Arch Gen Psychiatry 1989; 46: 672
73. Perry PJ, Miller DD, Arndt SV, et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991; 148: 231-5
74. Schooler NR, Levine J, Sever JB, et al. Prevention of relapse in schizophrenia. Arch Gen Psychiatry 1980; 37: 16-24
75. Davis JM, Barter JT, Kane JM. Antipsychotic drugs. In: Kaplan HI, Sadock BJ, editors. Comprehensive textbook of psychiatry, II. Baltimore: Williams and Wilkins, 1989: 1591-626
76. Kane JM. The current status of neuroleptic therapy. J Clin Psychiatry 1989; 50: 322-8
77. Small JG, Kellams JJ, Milstein V, et al. A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. Am J Psychiatry 1975; 132: 1315-7
78. Growe GA, Crayton JW, Klass DB, et al. Lithium in chronic schizophrenia. Am J Psychiatry 1979; 136: 454-5
79. Carmen JS, Bigelow LB, Wyatt RJ. Lithium combined with neuroleptics in chronic schizophrenic and schizoaffeclive patients. J Clin Psychiatry 1981; 42: 124-8
80. Lerner Y, Mintzer Y, Shestatsky M. Lithium combined with haloperidol in schizophrenia patients. Br J Psychiatry 1988; 153: 359-62
81. Angst J, Weiss P, Grof P, et al. Lithium prophylaxis in recurrent affective disorders. Br J Psychiatry 1970; 116: 604-14
82. Schulz SC, Kahn EM, Baker RW, et al. Lithium and carbamazepine augmentation in treatment refractory schizophrenia. In: Angrist B, Schulz SC, editors. The neuroleptic-nonresponsive patient: characterization and treatment. Washington, DC: American Psychiatric Press, 1990: 109-36
83. Neppe VM. Carbamazepine in non-responsive psychosis. J Clin Psychiatry 1988; 49: 22-8
84. Hakola HP, Lauluma VA. Carbamazepine in treatment of violent schizophrenic patients. Lancet 1982; 1: 1358
85. Herrera JM, Sramek JJ, Costa JF. Efficacy of adjunctive carbamazepine in the treatment of chronic schizophrenia. Drug Intell Clin Pharm 1987; 21: 355-8
86. Luchins B. Carbamazepine and neuroleptics in the treatment of schizophrenia. Psychopharmacol Bull 1984; 20: 569-71
87. Klein E, Beutal E, Lerer B, et al. Carbamazepine and haloperidol versus placebo and haloperidol in excited psychosis: a controlled study. Arch Gen Psychiatry 1984; 41: 165-70
88. Schulz SC, Kahn EM, Baker RW, et al. Lithium and carbamazepine augmentation in treatment-refractory schizophrenia. In. Angrist B, Schulz SC, editors. The neuroleptic-nonresponsive patient: characterization and treatment. Washington, DC: American Psychiatric Press, 1990: 190-36
89. Okumma T, Yamashita I, Takahashi R, et al. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenia and schizoaffective disorders. Acta Psychiatr Scand 1989; 80: 250-9
90. Sramek J, Herrera J, Costa J, et al. A carbamazepine trial in chronic treatment-refractory schizophrenia. Am J Psychiatry 1988; 145 (6): 748-50
91. Llorca PM, Wolf MA, Lancon C, et al. Clinical efficacy of bromocriptine, carbamazepine and cyproheptadine as adjuvant to neuroleptics in twenty four chronic resistant schizophrenics [in French]. Encéphale 1993; 19: 565-71
92. Kidron R, Averbuch I, Klein E, et al. Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia. Biol Psychiatry 1985; 20: 199-228
93. McElroy SL, Keck PE, Pope HG, et al. Valproate in psychiatric disorders: literature review and clinical guidelines. J Clin Psychiatry 1989; 50: 23-9
94. Wassef A, Watson DJ, Morrisson P. Neuroleptic-valproic acid combination in treatment of psychotic symptoms: a three cases report. J Clin Psychopharmacol 1989; 9: 45-8
95. Ko G, Korpi E, Freed WJ, et al. Effect of valproic acid on behavior and plasma amino acid concentrations in chronic schizophrenic patients. Biol Psychiatry 1985; 20: 199-228
96. Linnoila M, Viukar M, Hietal O. Effect of sodium valproate on tardive dyskinesia. Br J Psychiatry 1976; 129: 114-9
97. Nestoros JN, Suranyi-Cadotte BE, Spees RC, et al. Diazepam in high doses is effective in schizophrenia. Prog Neuro-Psychol Biol Psychiatry 1982; 6: 513-6
98. Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 1991; 148 (6): 714-26
99. Lingjaerde O, Engstrand E, Ellingsen P, et al. Antipsychotic effect of diazepam when given in addition to neuroleptics in chronic psychotic patients: a double-blind clinical trial. Curr Ther Res 1979; 26: 505-14
100. Lingjaerde O. Effect of the benzodiazepine derivative estazolam in patients with auditory hallucinations. Acta Psychiatr Scand 1982; 65: 339-54
101. Wolkowitz OM, Pickar D, Doran AR, et al. Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia. Am J Psychiatry 1986; 143: 85-7
102. Holden JM, Itil TM, Keskiner A, et al. Thioridazine and chlordiazepoxide, alone and combined, in the treatment of chronic schizophrenia. Compr Psychiatry 1968; 9: 633-43
103. Ruskin P, Averbrukh I, Belmaker RH, et al. Benzodiazepines in chronic schizophrenia. Biol Psychiatry 1979; 14: 557-8
104. Ratey JJ, Sorgi P, O'Driscoll GA, et al. Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study. J Clin Psychiatry 1992; 53 (2): 41-6
105. Lindström LH, Persson E. Propranolol in chronic schizophrenia: a controlled study in neuroleptic treated patients. Br J Psychiatry 1980; 137: 126-30
106. Yorkston NJ, Zaki SA, Weller MP, et al. DL-propranolol and chlorpromazine following admission for schizophrenia: a controlled comparison. Acta Psychiatr Scand 1981; 63: 13-27
107. Manchanda R, Hirsch SR. Does propranolol have an antipsychotic effect? A placebo-controlled study in acute schizophrenia. Br J Psychiatry 1986; 148: 701-7
108. Peet M, Beethell S, Coates A, et al. Propranolol in schizophrenia: I. Comparison of propranolol, chlorpromazine, and placebo. Br J Psychiatry 1981; 139: 105-11
109. Greendyke RM, Kanter DR. Plasma propranolol levels and their effect on plasma thioridazine and haloperidol concentrations. J Clin Psychopharmacol 1987; 7: 178-82
110. Brambilla F, Scarone S, Ponzano M, et al. Catecholaminergic drugs in chronic schizophrenia. Neuropsychobiology 1979; 5: 185-200
111. Gerlach J, Ludhdorf K. The effect of L-Dopa on young patients with simple schizophrenia, treated with neuroleptic drugs. Psychopharmacology (Berl) 1975; 44: 105-10
112. Inanaga K, Nakazawa Y, Inoue K, et al. Double-blind controlled study of L-Dopa therapy in schizophrenia. Folia Psychiatr Neurol Jpn 1975; 29: 123-43
113. Kay SR, Opler LA. L-Dopa in the treatment of negative schizophrenic symptoms: a single-subject experimental study. Int J Psychiatry Med 1985; 15: 293-8
114. Buchanan FH, Parton RV, Warren JW, et al. Double-blind trial of L-dopa in chronic schizophrenia. Aust NZ J Psychiatry 1975; 9: 269-71
115. Gattaz WF, Kollisch M. Bromocriptine in the treatment of neuroleptic-resistant schizophrenia. Biol Psychiatry 1986; 21: 519-21
116. Delay J, Deniker P. Méthodes chimiothérapiques en psychiatrie. Paris: Masson Ed, 1961: 496
117. Finn MHP, Nadolski F, Guy W, et al. Clinical, psychological, and myoneural changes in psychotic patients under oral Serpasil medication. J Nerv Ment Dis 1955; 122: 458-62
118. Gardner MJ, Hawkins HM, Judah LN, et al. Objective measurement of psychiatric changes produced by chlorpromazine and reserpine in chronic schizophrenia. Washington, DC: Psychiatric Research Reports of the American Psychiatric Association 1955; 1: 77-83
119. Hollister LE, Krieger GE, Kringel A, et al. Treatment of chronic schizophrenic reactions with reserpine. Ann NY Acad Sci 1955; 61: 92-100
120. Hollister LE, Traub L, Beckman WG. Psychiatric use of reserpine and chlorpromazine: results of double-blind studies. In: Kline NS, editor. Psychopharmacology. Washington, DC: American Association for the Advancement of Science, 1956
121. Naidoo D. The effects of reserpine (Serpasil) on the chronic disturbed schizophrenic: a comparative study of rauwolfia alkaloids and electroconvulsive therapy. J Nerv Ment Dis 1956; 123: 1-13
122. Gore CP, Egan GP, Walton D. The place of reserpine in the treatment of the chronic psychotic patient. Am J Psychiatry 1957; 114: 333-7
123. Shawver JR, Gorham DR, Leskin LW, et al. Comparison of chlorpromazine and reserpine in maintenance drug therapy. Dis Nerv Syst 1959; 20: 452-7
124. Berlant JL. Neuroleptics and reserpine in refractory psychoses. J Clin Psychopharmacol 1986; 6: 180-4
125. Bacher NM, Lewis HA. Long term reserpine use in selected refractory outpatients. Am J Psychiatry 1985; 142: 386-7
126. Weiner N. Drugs that inhibit adrenergic nerves and block adrenergic receptors. In: Gilman AG, Goodwin LS, Rall TW, et al., editors. The pharmacologic basis of therapeutics. 7th ed. New York: Macmillan Publishing Company, 1985: 181-214
127. Tuteur W, Lepson D. Combined reserpine-chlorpromazine therapy in highly disturbed psychotics. Am J Psychiatry 1955; 112 (3): 206
128. Siris SG, Morgan V, Fagerström R, et al. Adjunctive imipramine in the treatment of postpsychotic depression. Arch Gen Psychiatry 1987; 44: 533-9
129. Siris SG, Bermanzohn PC, Mason SE, et al. Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial. Arch Gen Psychiatry 1994 Feb; 51: 109-15
130. Bennett JL, Hamilton LD. Sequential use of antidepressant drug with chlorpromazine in chronic schizophrenia. Psychiatr Q 1963; 37: 53-66
131. Bucci L. The negative symptoms of schizophrenia and the monoamine oxidase inhibitors. Psychopharmacology (Berl) 1987; 91: 104-8
132. Goff DC, Brotman AW, Waites M, et al. Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. Am J Psychiatry 1990; 147: 492-4
133. Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on-double blind placebo-controlled study. Biol Psychiatry 1992; 31: 698-704
134. Angrist B, Peselow E, Rubinstein M, et al. Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology (Berl) 1982; 78 (2): 128-30
135. Cesarec Z., Nyam AK. Differential response to amphetamine in schizophrenia. Acta Psychiatr Scand 1985; 71: 523-8
136. Van Kammen DP, Boronov JJ. Dextro-amphetamine diminishes negative symptoms in schizophrenia. Int Clin Psychopharmacol 1988 Apr; 3 (2): 11-21
137. Van Kammen DP, Peters JL, van Kammen WB, et al. Clonidine treatment of schizophrenia: can we predict treatment response? Psychiatry Res 1989; 27: 297-311
138. Tamminga CA, Gotts MD, Thaker GK, et al. Dopamine agonist treatment of schizophrenia with n-propylnorapomorphine. Arch Gen Psychiatry 1986; 43: 398-402
139. Tandon R, Mann NA, Eisner WE, et al. Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients. Psychiatry Res 1990; 31: 235-41
140. Correa N, Opler LA, Kay SR, et al. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J Clin Psychoparmacol 1987; 7 (2): 91-5
141. Brambilla F, Scarone S, Pugnetti L, et al. Bromocriptine therapy in chronic schizophrenia: effects on symptomatology, sleep patterns, and prolactin response to stimulation. Psychiatry Res 1983; 8: 159-69
142. Manji HK, Lander M. Bromocriptine in neuroleptic resistance. Biol Psychiatry 1987; 22: 523-4
143. Levi-Minzi S, Bermanzohn PC, Siris SG. Bromocriptine for 'negative' schizophrenia. Compr Psychiatry 1991; 32 (3): 210-6
144. Brambilla F, Gessa GL, Sciascia A, et al. Treatment of drug-resistant chronic schizophrenics with an association of neuroleptics and the calcium antagonist nimodipine. Eur Psychiatry 1992; 7: 177-82
145. Pickar D, Wolkowitz OM, Doran AR, et al. Clinical and biochemical effects of verapamil administration to schizophrenic patients. Arch Gen Psychiatry 1987; 44: 113-8
146. Gulmann NC, Bahr B, Andersen B, et al. A double-blind trial of baclofen against placebo in the treatment of schizophrenia. Acta Psychiatr Scand 1976; 54: 287-93
147. Kaminsky R, Moriarty T, Wolf D, et al. Famotidine a histamine H2 receptor antagonist and negative symptoms of schizophrenia. Biol Psychiatry 1991; 29: 67-8
148. Berger PA, Barchas JD. Pharmacology studies of beta-endorphin in psychopathology. Psychiatr Clin North Am 1983; 6: 377-91
149. Meltzer HY, Busch DA, Tricou BJ, et al. Effect of (des-tyr)-gamma-endorphin in schizophrenia. Psychiatry Res 1982; 6: 313-6
150. Brizer DA, Hartman N, Sweeney J, et al. Effect of methadone plus neuroleptics on treatment-resistant chronic paranoid schizophrenia. Am J Psychiatry 1985; 142: 1106-7
151. Naber D, Munch U, Wissmann J, et al. Naloxone treatment for five days ineffective in schizophrenia. Acta Psychiatr Scand 1983; 67: 265-71
152. Gitlin MJ, Gerner RH, Rosenblatt M. Assessment of naltrexone in the treatment of schizophrenia. Psychopharmacol (Berl) 1981; 74: 51-3
153. Inanaga K, Nakano T, Nagat T, et al. Behavioral effects of protirelin in schizophrenia. Arch Gen Psychiatry 1978; 35: 1011-4
154. Brambilla F, Boniolotti GP, Maggioni M, et al. DDAVP therapy in chronic schizophrenia: effects on negative symptoms and memory. Neuropsychobiology 1988; 20: 113-9
155. Nair NPV, Bloom DM, Nestoros JN, et al. Therapeutic efficacy of cholecystokinin in neuroleptic-resistant schizophrenic subjects. Psychopharmacol Bull 1983; 19: 134-6
156. Peselow E, Angrist B, Sudilovsky A, et al. Double blind controlled trials of cholecystokinin octapeptide in neuroleptic-refractory schizophrenia. Psychopharmacol 1987; 91: 80-4
157. Marshall BD, Glynn SM, Midha KK, et al. Adverse effects of fenfluramine in treatment refractory schizophrenia. J Clin Psychopharmacol 1989; 9 (2): 110-5
158. Ban TA, Lehmann HE, Deutsch M. Negative findings with mega-vitamins in schizophrenic patients: preliminary report. Commun Psychopharmacol 1977; 1: 119-22
159. Salzman C. The use of ECT in the treatment of schizophrenia. Am J Psychiatry 1980; 137: 1032-41
160. Fink M. Convulsive therapy: theory and practice. New York: Raven Press, 1985
161. Small JG. Efficacy of electroconvulsive therapy in schizophrenia, mania, and other disorders: I. Schizophrenia. Convuls Ther 1985; 1: 263-70
162. Friedel RO. The combined use of neuroleptics and ECT in drug resistant schizophrenic patients. Psychopharmacol Bull 1986; 22 (3): 928-30
163. Gujavarty K, Greenberg LB, Fink M. Electroconvulsive therapy and neuroleptic medication in therapy-resistant positive-symptom psychosis. Convuls Ther 1987; 3 (3): 185-95
164. Milstein V, Small JG, Miller MJ, et al. Mechanisms of action of ECT: schizophrenia and schizoaffective disorder. Biol Psychiatry 1990; 27: 1282-92
165. Klapheke MM. Combining ECT and antipsychotic agents: benefits and risks. Convuls Ther 1993; 9 (4): 241-55
166. Smith K, Surphlis WRP, Gynther MD. ECT-chlorpromazine and chlorpromazine compared in the treatment of schizophrenia. J Nerv Ment Dis 1967; 144: 284-90
167. Taylor P, Fleminger JJ. ECT for schizophrenia. Lancet 1980; i: 1380-2
168. American Psychiatric Association. The practice of ECT: recommendations for treatment, training and privileging. Convuls Ther 1990; 6 (2): 85-100
169. Malm U. Good routine treatment in schizophrenia. In: Dencker SJ, Kulhanek F, editors. Treatment resistance in schizophrenia. Braunschweig/Wiesbaden: Vieweg, 1988: 34-43
170. Haakenaasen J, Ugelstad E. What is effective in the psychosocial treatment of younger, chronic schizophrenic inpatients? A 10 years follow-up study. Nord Psykiatr Tidsskr 1986; 40: 255-65
171. Ugelstad E. Success and failure in individual psychotherapy with psychotic patients. Some follow-up considerations. Nord Psykiatr Tidsskr 1985; 39: 279-84
172. Goldstein MJ. Individual and family therapy of schizophrenia. In: Decker SJ, Kulhanek F, editors. Treatment resistance in schizophrenia. Braunschweig/Wiesbaden: Vieweg, 1988
173. May PR. A step forward in research on psychotherapy of schizophrenia. Schizophr Bull 1984; 10: 564-98
174. Liberman RP, Van Putten T, Marshall BD, et al. Optimal drug and behavior therapy for treatment-refractory schizophrenic patients. Am J Psychiatry 1994; 151 (5): 756-9
175. Rosberg J, Stunden AA. The use of direct confrontation: the treatment-resistant schizophrenic patients. Acta Psychiatr Scand 1990; 81: 352-8
176. Tarrier N, Beckett R, Harwood S, et al. A trial of two cognitive-behavioural methods of treating drug-resistant residual psychotic symptoms in schizophrenic patients: I. Outcome. Br J Psychiatry 1993; 162: 524-32
177. Mirza S, Sunil Babu V, Vithayathil E. Treatment resistance in schizophrenia [letter]. Br J Psychiatry 1993; 162: 524-32
178. Chadwick P, Birchwood M. The omnipotence of voices. A cognitive approach to auditory hallucinations. Br J Psychiatry 1994; 164: 190-201
179. Liberman JA. Rehabilitation psychiatrique des malades mentaux chroniques. Paris: Masson Ed, 1991
180. Kuehnel TG, Liberman RP, Marshall BD, et al. Optimal drug and behavior therapy for treatment-refractory institutionalized schizophrenics. In: New directions for mental health services. Geneva: World Health Organization, 1992; 53: 67-78
181. Kuehnel TG, Liberman RP, Marshall BD, et al. Optimal drug and behavior therapy for treatment-refractory institutionalized schizophrenics. New Dir Ment Health Serv 1992; 53: 67-78
182. Garety PA, Kuipers L, Fowler D, et al. Cognitive behavioural therapy for drug-resistant psychosis. Br J Med Psychol 1994; 67: 259-71